Investigating the Etiology of Primary Failure of Eruption (PFE): A Comprehensive Phenotypic and Genetic Analysis by Hendricks, Heather
Investigating the Etiology of Primary Failure of Eruption (PFE): A Comprehensive 
Phenotypic and Genetic Analysis 
 
 
 
Heather Morgan Hendricks 
 
 
 
 
A thesis submitted to the faculty of the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Master of Science in the School of Dentistry 
(Orthodontics). 
 
 
 
 
Chapel Hill 
2015 
 
 
 
 
Approved by: 
Sylvia A. Frazier-Bowers 
 
Sompop Bencharit 
 
Kimon Divaris 
 
J. Timothy Wright   
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2015 
Heather Morgan Hendricks 
ALL RIGHTS RESERVED 
iii 
ABSTRACT 
Heather Morgan Hendricks:  Investigating the Etiology of Primary Failure of  
Eruption (PFE): A Comprehensive Phenotypic and Genetic Analysis 
(Under the direction of Sylvia A Frazier-Bowers) 
The genetic basis of PFE (OMIM ID: 125350), a diagnosis that conveys a poor prognosis 
in the eruption/ function of teeth, was interrogated. Treatment with a continuous archwire 
worsens the condition. Two aims tested the hypothesis that PTH1R mutations result in loss of 
function and that multiple genes cause PFE: to determine 1) the fate of a functional PTH1R 
mutation and 2)PFE contribution by BMP2 and TNFSF-11. Methods: We used IFA and 
transfected COS7 cells with either the WT or 1092delG PTH1R mutation sequence to compare 
the fate of the expressed protein and performed mutational analysis of BMP2 and TNFSF-11 
with PCR and sequencing. Results: Sequencing revealed 3 intronic SNPs in TNFSF-11; in silico 
/functional studies showed expression alterations and structural changes in mutant vs WT 
PTH1R protein. Conclusion: PTH1R mutations in PFE likely result from diminished function; 
causative mutations in genes.   
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INVESTIGATING THE ETIOLOGY OF PRIMARY FAILURE OF ERUPTION (PFE): A COMPREHENSIVE 
PHENOTYPIC AND GENETIC ANALYSIS 
Introduction 
Background and Significance 
The process of normal tooth eruption is an integral part of normal tooth development 
and a thorough understanding of the biologic underpinnings is critical for any dental 
practitioner.  Every member of the dental team needs to have a comprehensive and functional 
understanding of the patterning and sequencing of eruption in order to provide optimal care. 
The ability to develop a prioritized diagnosis and treatment plan as a result of this knowledge is 
especially important for the practicing clinician and therefore makes expanding our 
understanding of this biologic process (i.e. eruption) more critical. This knowledge also includes 
the ability to understand when to refer a patient to a specialist, who may be better trained to 
treat certain diagnoses. The literature has identified and described many different etiologies of 
eruption disturbances that are not uncommon occurrences within the dental practice, however, 
the critical step in diagnosing eruption disorders lies in first identifying its etiology out of the 
wide range of possibilities.1, 7, 29 It is understood that eruption disorders may stem from local 
and non-syndromic causes (cysts, ankylosis, lateral tongue pressure, supernumerary teeth, 
thumb habit,) 1, 3 or may manifest as part of a genetic syndrome (Cleidocranial Dysplasia, 
Hunter’s Disease and Osteopetrosis)(Figure 1).1 
2 
Eruption Disorders and Diagnostic Approaches 
Three categories of eruption disorders exist within the broad spectrum of local/non-
syndromic causes.2 These are Mechanical Failure of Eruption (MFE), ankylosis, and the more 
perplexing- Primary Failure of Eruption (PFE) (OMIM ID: 125350). MFE is defined an eruption 
failure due to a mechanical obstruction of a tooth’s eruption pathway- which can often be 
treated successfully with the removal of the mechanical blockage due to a correct diagnosis.8,13 
Ankylosis is defined as the occurrence when the cementum on the root of the tooth fuses 
directly to the bone, thereby eliminating the periodontal ligament space (PDL) and halting 
spontaneous eruption potential.3, 4 However the primary diagnosis is based on clinical 
appearance; this often includes infraocclusion relative to the adjacent teeth.  An important 
adjunctive diagnostic approach is the diagnosis of ankylosis through radiographic examination; 
this is based largely on identifying locations of an absence of a visible periodontal ligament 
space. However, the diagnosis of ankylosis is frequently more subjectively based on the lack of 
clinically-appreciable mobility, and a sharp sound noted upon tooth percussion with a metal 
object.5 It is important to realize the limitations of these diagnostic techniques, in addition to 
their applications. Currently, the only two ways to definitively diagnose an ankylosed tooth is to 
apply orthodontic force and wait for the tooth to move, or to luxate the tooth and achieve 
visual mobility. The ability to implement advanced imaging is a promising tool, however, when 
evaluating a two dimensional radiograph, the appearance of PDL fusing to bone can either be 
overstated or completely undetected; this is in part due to the ability, or inability, to 
radiographically image mineralized tissue that falls within a specific range of density and size. 
6,13 To date, there have been no investigations evaluating the ability to diagnose ankylosis using 
3 
a Cone Beam CT scan of any size or resolution. Even though the large field of view CBCT scans 
have an average resolution of 0.3-0.4 voxels 6, this is still an inadequate resolution to evaluate 
whether a fusion of cementum and bone exists. The important goal in distinguishing ankylosis 
from other eruption problems is that unlike PFE, the ankylosed tooth can be extracted and the 
remaining teeth will likely be responsive to orthodontic treatment.4  The challenge is however 
that ankylosis can often be confused with the more enigmatic Primary Failure of Eruption 
(Figure 2). 2 
Primary Failure of Eruption is poorly understood but clearly falls within the spectrum of 
Local/Non-syndromic eruption disruptions. First described at UNC by Proffit and Vig (1981), PFE 
is clinically marked by failure of permanent (adult) tooth eruption in the absence of mechanical 
obstruction, and affects only the posterior dentition.7 The use of the term, primary, denotes 
that the defect is located in the eruption mechanism of the tooth itself.8 PFE diagnosis has been 
characterized by distinction of two different patterns of clinical presentation: Type 1 PFE and 
Type 2 PFE. Type 1 PFE presentation consists of a progressive, anterior-posterior lateral open 
bite that worsens distal to the most mesially positioned PFE-affected tooth; Type 2 PFE 
presents with a more varied pattern of infra-eruption distal to the most mesially affected 
tooth.18 An early possible treatment of isolated ankylosis of permanent first molars can be 
managed via the extraction of the offending ankylosed tooth; this will allow for normal eruption 
of the second and third molars. The failure of the second and third molars to fully erupt would 
be pathognomonic for PFE.30 This selective extraction pattern is a potential treatment for a 
patient who presents to the clinic before the eruption of the permanent second molars; 
however, the typical sequela for PFE affected individuals is unfortunately the high morbidity of 
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complex surgical intervention and multiple tooth extractions required to restore form and 
function (Figure 3).   
From a treatment standpoint these cases are complicated; if traditional orthodontics is 
attempted the condition only worsens (Figure 1). Taken together, this supports that the 
diagnosis of PFE conveys a poor prognosis in the normal eruption and function of teeth. 8 
Recent investigations that have focused on PFE and other eruption disorders have simply done 
so from an etiologic perspective (i.e., no consideration as to how the etiology relates to the 
phenotype and proposed management has been combined for a holistic picture of the 
disorder).  The discovery and association of PFE with the parathyroid one hormone receptor 
gene, PTH1R (discussed below), opens a new dimension of investigation; the role of the PTH1R 
gene alone may substantially contribute to our understanding of developmental processes 
beyond tooth eruption.8, 9, 16 
PTH1R and PFE 
Since the original description of PFE, investigations of its etiology have been completed 
by multiple researchers; a major commonality among these documented studies of PFE is the 
identification of mutations in the PTH1R gene.  Currently, autosomal dominant mutations in the 
(PTH1R) gene have been identified as the only concrete cause of PFE.2,8, 9, 16, 17, 18, 30 This recent 
genetic discovery associated with PFE represents a breakthrough, creating a paradigm shift in 
diagnostic and clinical approaches. PFE and its connection with PTH1R not only reveals another 
dimension of inquiry into the aspects of dental eruption pattering, but it obviates the gaps in 
knowledge that exist in terms of how this gene may be integrated within the odontogenic code 
and what, if any relationship the PTH1R-associated dental phenotype has with the overall 
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systemic health.13,20  For example, the fact that PFE that solely expresses as a dental problem, 
now understood to be a genetic disorder caused by PTH1R, is implicitly connected to systemic 
processes that are also governed by this gene.  Hence, the isolated genotype:phenotype 
relationship between PTH1R and PFE presents an interesting conundrum.18  A deeper 
understanding of the PTH1R gene may offer insights as to why this presents in clinically diverse 
conditions; such as Jansen’s Metaphyseal  Chondrodysplasia (OMIM ID: 156400).  
Bloomstrand’s Lethal Chondrodysplasia (OMIM ID: 215045),   Enchondromatosis (Ollier’s 
Disease) (OMIM ID:  166000), osteoarthritis, and PFE.28 Briefly, Jansen’s is caused by autosomal 
dominant heterozygous mutations in PTHR1 resulting in short-limbed dwarfism (Figure 4).28 
Ollier’s disease is also correlated to an autosomal dominant mutation, which is characterized by 
multiple enchondromas located primarily in the metaphyseal shafts of long bones; having the 
ability to develop into chondrosarcomas. Bloomstand’s, however, exhibits a recessive PTHR1 
mutative deactivation which results in early lethality, shortened limbs, and premature bone 
maturity (Figure 5).28 The variation of clinical presentations of both dominant and recessive 
autosomal mutations within the same gene make its inquiry that much more interesting, and 
exhibits why PFE, having more relatively benign effects, could be a potential model of PTH1R 
gene studies. Although studies completed in this project cannot fully answer these questions, 
they provide the impetus for future studies that will unravel these mysteries. 
PTH1R: A G-protein coupled receptor 
While the varied functions and interactions of PTH1R are indeed intriguing, one of the 
more interesting aspects of PTH1R is that it belongs to a very specific group of cell membrane-
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bound G-protein coupled receptors (GPCR), called Class II (Family B) receptors that contain 7-
transmembrane helecies.11 In humans, PTH1R is located on chromosome 3 (3p22-p1.1), has 14 
coding exons, 3 non-coding exons, and 3 promoter regions (Figure 6).28  Regardless of the 
species, PTH1R function is based on two key interactions: 1) the interaction between the c-
terminus of the Parathyroid hormone(PTH)/Parathyroid hormone-related peptide (PTHrP) with 
the N-terminus of the receptor, and 2) the interaction between the N-terminus of the receptor 
with its transmembrane region.28 It is highly concentrated in the skeletal muscles, liver, kidneys, 
and bone and has the ability to bind to multiple ligands.  Depending on which ligand it binds to 
(either PTH or PTHrp), it is responsible for a plethora of somatic functions (endochondral 
ossification, tooth eruption, or osteogenesis regulation).  The PTH1R molecule is also a rather 
interestingly ‘promiscuous’ receptor, in that it can bind to a multitude of different G-proteins, 
which alter the type of action initiated via its signal transduction.33   
PTH1R primarily binds to the stimulatory subfamily of G-proteins (Gs), which in turn 
stimulates the activation of adenylyl cyclase (AC) and the production of cAMP. cAMP then binds 
to the regulatory subunit of protein kinase A (PKA), which results in a fully active catalytic 
subunit.33 This subunit acts as an important mediator in gene transcription and also plays a 
large part in gene transactivation, through the action of PKA phosphorylyzing the cAMP 
response element binding protein (CREB).  PTH1R can also bind to the subclass Gq/11 protein, 
which results in the sequela of the activation of phospholipid C, inositol triphosphates (IP3), and 
diacylglycerol (DAG).33  This results in the release of intracellular calcium, and the production of 
protein kinase C (PKC). A third class of proteins that PTH1R can bind to is the subfamily on 
inhibitory G-proteins (Gi/o), which bind to and inhibit AC, consequently reducing production of 
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cAMP. This pathway also activates the production of phospholipid C(PLC), resulting in increased 
intracellular calcium levels, via either calcium-channel mediated influx or intracellular calcium 
stores. Another interesting G-protein subfamily that PTH1R can bind to is the G12/13 group.33 This 
pathway occurs primarily in osteoblastic cells, and imitates activity through the activation of 
phospholipid D.33  
It is known that a majority of DNA is either ultimately translated into a protein with a 
primary, secondary, tertiary, and quaternary structure, or it indirectly affects protein function. 
It is also known that the sequence of the DNA affects the structures of the protein, and 
therefore expresses as numerous functions.10 Accordingly, alterations in the DNA sequence of 
PTH1R can directly affect the structure and behavior of the resultant protein.   The literature 
has nicely illustrated that the 2nd and 3rd intracellular loops are the most important for G-
protein binding, and that the N-terminus and 3rd intracellular loop are most functionally 
sensitive to mutations. The importance of the 2nd and 3rd loops in connection to their 
responsibility surrounding G-protein binding has been used as a basis of interrogation in various 
labs, and it offers support towards the concept of competitive binding for Gs and Gq/11.11,27, 28  It 
is also important to note that the C-terminus is most robust in terms of G-protein interaction. 
The fact that PHT1R has a direct pathogenic effect leading to PFE, and because of its relative 
reduced mortality as compared to other conditions caused by mutations in PTH1R (e.g. lethal 
dwarfism) it becomes an ideal model to further investigate the function of PTH1R at both ends 
of the spectrum – systemic and somatic effect versus localized effect resulting from different 
mutations.28 Through a careful review of the literature and our current findings, it is understood 
that alterations in molecular pathways that underlie normal eruption can result in an eruption 
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disorder; and that early detection and management of these situations provides the best 
chance at a successful treatment outcome.1, 2 Inaccurate diagnosis will most certainly lead to 
suboptimal treatment choices, which ultimately hold negative consequences for the patient. 
Previous PTH/PTHrp and PTH1R Studies: 
PTH1R, PTH, and PTHrP have been the focus of numerous inquiries; our understanding 
of their functions and interactions are improving at a slow but steady pace. We have benefited 
from functional studies of the PTH/PTHrP/PTH1R pathway.   For instance, Ouyang et al have 
shown that PTHrP plays an important role in cementum biomineralization.24 Not only is PTHrp 
and PTH1R crucial in the maintenance of calcium homeostasis, but each compound is found in 
significant concentrations in cementoblasts.  While this demonstrates the important function of 
PthrP and PTH1R in cementogenesis, it is important to note that periodontal ligament (PDL) 
cells provide the osteoclast precursor cells needed to clear the eruption pathway.10 Studies 
have shown that within PDL cells, PTHrP increases the relative level of TNFSF-11 expression 
versus osteoprotegerin (OPG) through a cAMP/PKA-independent pathway, thereby increasing 
the amount of osteoclastogenesis.24 Collectively, this information reveals an obvious and 
intimate connection with the PTH1R pathway and tooth eruption, but the specific pathogenesis 
that leads to an eruption disorder versus a systemic disease is still elusive.10   
We can begin to understand the more enigmatic aspects of the role of PTH1R and tooth 
eruption by starting with an understanding of the interaction of the receptor to the ligand. 
Previous studies using mutated PTH1R and PTH revealed that the most important aspect of 
receptor activation was the interaction of the ligand with the transmembrane region of 
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PTH1R.28 Specifically, Shimizu and collaborators proved that a truncated ligand, as small as 14 
amino acids, resulted in the production of similar basal cAMP levels- whether it interacted with 
the mutated PTH1R that was missing its extracellular N-terminus, or if it bound to the WT 
PTH1R. This further showed that binding and affinity assays with COS7 cells revealed that the 
most important factor for the activation of the receptor was the interaction of its 
transmembrane region with the ligand.26 Rickard completed an activity-based PTH1R assay 
identifying a small molecular ligand for the receptor that acts as a weak, micromolar agonist. 
This proposed allosteric mechanism offers a theoretical construct for future therapeutic 
approaches for diseases linked to PTH1R disorders, such as osteoporosis or osteoarthritis.28 
Epidemiology  
The logical first step to further dissection and characterization of the clinical and 
molecular defect is to take advantage of the already vast database of eruption disorders in the 
UNC Department of Orthodontics.   To date, no epidemiological studies have been completed 
to provide the exact incidence of PFE, but it has been estimated to occur in almost 1% of the 
world-wide population.30 The fact that this condition is often under-diagnosed and thereby 
improperly treated- suggests a prevalence that is likely higher than its estimated 1%.9 This 
modest estimate does not account for the more common clinical problem – delayed tooth 
eruption. Tooth eruption anomalies occur in a significant segment of the population causing 
problems such as inability to chew and digest food properly in addition to esthetic issues that 
affect the quality of life for affected individuals.  While the effects of PFE are not nearly as 
dramatic compared to other disorders related to PTH1R mutations, the use of PFE as a model 
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for PTH1R study will allow for the attainment of an improved understanding surrounding the 
actions of PTH1R and PTH/PTHrP in the dental and somatic system.  
The aims completed in this study further investigate the molecular genetic basis of 
primary failure of eruption (PFE) as well as characterize the corresponding clinical presentation. 
Our understanding of the pathogenesis of PFE in relationship to mutations in the PTH1R gene 
will aid us in elucidating the mechanism of PTH1R in the somatic system, the pathogenesis of a 
PTH1R mutation, and allow us to add to the body of knowledge defining the eruption process in 
general.   We report here the completion of two aims that tested the hypothesis that PTH1R 
mutations result in a loss of function and that several potential genes cause PFE.  Aim 1 utilized 
functional studies to determine the consequence of a functional PTH1R mutation (mut) 
compared to wildtype (WT), and Aim 2 evaluated the contribution of two candidate genes, 
BMP2 and TNFSF-11.  
The collective body of work presented here reveals that differences exist in the 
expression (localization and intensity) of the PTH1R protein in the mutant vs WT. These studies 
represent a promising prelude to definitive quantitative and functional studies. We also sought 
to understand whether other genes known to be in the PTH1R pathway (Ingenuity Pathway 
Analysis) were found to harbor mutations in individuals with cleared clinical phenotype of PFE. 
This did reveal Single Nucleotide Polymorphisms (SNPs) in TNFSF-11 vs. BMP-2, however further 
analyses, and more importantly WES, may reveal additional genes that contribute to the PFE 
phenotype. Taken together, these findings and the future studies that will derive from it are of 
paramount importance, because it enriches our current diagnostic regime of eruption disorders 
by utilizing genetic data.  The future of medicine and dentistry will undoubtedly rely on the 
11 
precision of personal medicine; using genetic information in order to arrive at an accurate 
diagnosis and to thereby develop an appropriate treatment plan. 
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CHAPTER ONE 
INVESTIGATING THE PROTEIN EXPRESSION OF WT AND MUTANT PTH1R IN COS7 CELLS 
Introduction 
Eruption disorders represent multifactorial, and therefore clinically challenging entities 
to diagnose.2, 7, 8 The multifactorial aspect in combination with a limited understanding of the 
etiology and mechanism that leads to this problem translates into an elusive phenomenon. 
Specifically, the genetic basis of one category of eruption failure, Primary Failure of Eruption 
(PFE) (OMIM ID: 125350), has recently revealed the molecular basis of this disorder but the 
specific pathogenesis has yet to be elucidated.2,9 Moreover, it is known that autosomal 
recessive mutation in the very same gene that causes PFE, parathyroid hormone-1 receptor 
gene (PTH1R), leads to lethal conditions and PFE, which is limited to the dental units.17 One of 
the most fascinating aspects of PTH1R function is the juxtaposition of clinical presentations (i.e. 
lethal versus localized). Moreover, the PTH1R gene, which is known to regulate calcium 
homeostasis and bone metabolism, warrants further interrogation of this interesting receptor 
and the associated biologic/clinical phenomenon.  
 PTH1R: A G-protein coupled receptor (GPCR) 
PTH1R is a G-protein coupled receptor (GPCR) bound at the membrane of a cell and has 
the ability to bind either to PTH or PTHrP.15, 17  It is found throughout the body, but is highly 
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concentrated in the skeletal muscles, liver, kidneys, and bone.8 The function of PTH1R is 
determined whether its activating ligand is PTH or PTHrP; these corresponding functions are 
responsible for a broad spectrum of systemic processes (endochondral ossification, tooth 
eruption, mammary gland development, or osteogenesis regulation). Moreover, the PTH1R 
receptor is also a rather interestingly ‘promiscuous’ receptor, in that is can bind to many 
different G-proteins, which alter the type of action initiated via its signal transduction 
pathway.33  
The PTH1R receptor consists of an N-terminus, C-terminus, 3 extracelluar loops, 3 
intracellular loops, and 7 transmembrane (TM) loops. The literature has shown that the 2nd and 
3rd intracellular loops (attach TM3/4 and TM5/6, respectively) are the most important for 
efficient initial G-protein binding, and that the N-terminus and 3rd intracellular loop are most 
functionally sensitive to mutations.33 The understanding that the 2nd and 3rd loops are 
responsible for G-protein binding has been used as a basis of interrogation in various labs, 
offering support for the concept of competitive binding for Gs and Gq/11.33 It is also important to 
note that the C-terminus is most robust for G-protein interaction. The GPCR mechanism 
represents an integral aspect of many drug delivery systems making the pharmacogenetic 
impact of future PTH1R discoveries significant.10 Since PHT1R has been proven to be causative 
in the development of PFE, the relatively milder phenotype resulting from a PTH1R mutation 
provides the potential to use PFE as a “low-morbidity level” model to further investigate the 
function of PTH1R.  Accordingly, the localized defect observed in PFE versus the more severe 
and often lethal phenotype observed in Bloomstrand’s (OMIM ID: 215045) or Eiken’s Syndrome 
(OMIM: 600002), suggest a robust defect in general to further investigate the pathogenesis of 
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PTH1R (Figure 2.1 ((http://www.eurorad.org/eurorad/case.php?id=1463) and Figures 2.2a/b 
((Frazier-Bowers et al 2013)). Based on the literature and our current findings, it is understood 
that alterations in molecular pathways that underlie normal eruption can result in an eruption 
disorder; and that early detection and management of these situations provides the best 
chance at a successful treatment outcome.1, 2  Inaccurate diagnosis will most certainly lead to 
suboptimal treatment choices, which ultimately hold negative consequences for the patient.  
The remaining question of how an understanding of the mechanism that leads to PFE can 
potentially improve diagnosis and treatment and these studies present a logical first step to 
accomplishing this. 
PTH/PTHrP and Dental Eruption 
 
 In order to elucidate the function of PTH1R, it is imperative to understand the 
behaviors of its ligands. This is especially important in the inquiry of PFE and PTH1R because 
while more is understood about PTH1R and its activators in the skeletal and endocrine systems, 
less is known about its behavior in the dental tissues. PTHrP has been shown to be integral in 
the process of tooth eruption by its presence and activity in the enamel organ, specifically the 
stellate reticulum of the dental follicle.25 Studies have shown that the absence of PTHrP 
production of the dental follicle cells (via conditional-PTHrP knockout mice), initially normally 
developing teeth eventually become impacted and encapsulated by a bony crypt. This is due to 
the failure of the formation of an eruption pathway, and fusion of the cementum to the 
alveolar bone (ankylosis).25  It has been demonstrated that the cAMP/PKA pathway is largely 
responsible for the varying effects of PTHrP and PTH regulation of mineralized tissues.28 Due to 
the intricacy of up and downstream signal modulation and cis-element interactions, it is 
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supported that the signaling effect of PTHrP or PTH relies on the net outcome of cell’s 
integration into multiple signaling pathways. This explains why the activation of the Gs 
protein/cAMP/PKA pathway can result via PThrP or PTH, with each resulting in different 
downstream pathways, yet yielding a constitutively singular result. When concerning the dental 
unit, activation of the cAMP/PKA pathway (via Gs protein activation) by either ligand results in 
the progression of tooth development and eruption- while the disruption of the same pathway 
results in ankylosis (up-regulation of the biomineralization of cementoblasts) and a failure to 
erupt-secondary to a blocked eruption pathway.10  
         Similarly, in the skeletal system, the targeted loss of PTH1R is accompanied by 
impaired chondrocyte proliferation and accelerated maturation and calcification of 
chondrocytes, which mimics the loss of Gs (activation of cAMP and the PKA pathway).10 
Clinically, inactivating mutations in PTH1R results in hypocalcaemia and Bloomstrand’s 
chondroplasia (OMIM ID: 215045). Constitutively activating mutations of PTH1R lead to 
hypercalcemia and Jansen’s metaphyseal chondroplasia (OMIM ID: 156400).  Loss of 
parathyroid hormone (PTH) results in the aberrant formation of primary spongiosa of long bone 
and defective mineralization.20 This is in contrast with PFE (OMIM ID: 125350), which has 
numerous documented PTH1R mutations, yet it is isolated within the dental units, which 
increases the intrigue of the interactions between PFE, PTH1R, and PTH/PTHrP. These findings 
also point towards future studies involving further interrogation of PTH/PTHrP up/downstream 
signaling pathways and specific functional assays.  
 We therefore seek to understand the functional consequence of specific mutations in 
individuals that were identified with PFE. Our hypothesis is that PTH1R mutations identified in 
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PFE result in a loss of function. We speculate that this loss of function could be connected to an 
aberration in localization of the protein or G-binding. The studies presented in this report, 
taken together, reveal that differences do exist between the expressive localization of the WT 
versus mutant PTH1R. Further studies with specific binding assays will allow us to elucidate 
more precise mechanistic flaws that lead to PFE.      
Materials and Methods 
Transformation and Plasmid Prep of E.Coli 
The pcDNA™3.1 (+) Mammalian Expression Vector (5.4kb) (Figure 2.3) was used to create 
the construct containing the wild type human PTH1R sequence, named TG682 7260.  TG682 
7260 was generously donated from the Gardella laboratory (Massachusetts General Hospital, 
Boston, Massachusetts) for the functional studies (Figure 2.4).  Transformation of competent 
Escherichia coli DH5α cells (purchased from Invitrogen) was completed for the TG682 7260. 
Transformed E coli was grown to a logarithmic stage in LB broth (1.0% tryptone, 0.5% yeast 
extract, and 1% NaCl) and LB agar (1.0% tryptone, 0.5% yeast extract, 1% NaCl and 1.5% agar) 
medium were used.  IPTG (100 mg/ml) and Ampicillin (100 mg/ml) for the preparation of agar 
plates for growth, incubation was done at 37°C. After transforming the E. coli cells, 50 uL of the 
cell suspension was plated overnight at 37°. A single clone was selected for mid-scale plasmid 
preparation (NucleoBond® Xtra Midi, Macherey-Nagel GmbH & Co. KG), and was performed as 
per the provided protocol. All media was prepared according to the manufacturer’s 
recommendations.   
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Tissue Culture  
The COS7 cell line was generously donated by Dr. Sompop Bencharit and cultured in 
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 100 U/ml 
penicillin, and 100 µg/ml streptomycin. The cells were then typsinized and re-plated on 8-well 
glass chamber slides in preparation for transient transfection. 
Site-Directed Mutagenesis  
Site-Directed Mutagenesis was performed (Genscript ©) on the TG682 WT PTH1R vector 
to create the 1092delG PTH1R construct (Figures 2.5a and 2.5b). The mutated 1092delG vector 
was then transfected into COS7 cells for comparison with the WT PTH1R. 
Transfection of COS7 Cells  
Exponentially growing COS7 cells were plated on a glass 8-well chamber slide. 
Transfection was performed using FUGENE 6™ (Roche Applied Science) and Immunoflourence 
assay (IFA) studies were performed according to standard protocols. Briefly, cells were grown 
on a glass chamber slide, and grown to a density of 70% confluence prior to adding the DNA 
mixture, including 0.1 mg/ml of the vector containing the WT-PTH1R or mutant insert. The cells 
were transfected with either: the vector containing the human functional mutation (1092del G), 
or the wildtype PTH1R insert.  The polyclonal anti-PTH1R antibody used for IFA was purchased 
from Abcam ©, and the secondary FITC 546 goat anti-rabbit antibody (Life Technologies ©, 
Thermo Fischer Brand Inc.) was generously donated from the Webster-Cyriaque laboratory. 
Transfection of COS7 cells with the pcDNA3.0 (+GFP insert) for 48 hours was completed as an 
approximation of transfection efficiency. The transfection efficiency was estimated to be 70% 
(Figure 2.6). 
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IFA Studies 
Initial imaging of the WT PTH1R cells under a confocal microscope, illustrated that fact 
that transport vesicles were of the most notable prominence, with little evidence of cell 
membrane localization (Figure 2.7). This supported the selection of a 48-hours post transfection 
standard to evaluate WT vs Mutant PTH1R localization to the cell membrane. 
After 24 and 48 hours, the transfected COS7 cells were fixed for 15 minutes with -20 °C 80% 
Acetone in PBS at 25°C. Nonspecific binding was blocked by incubation of the COS7 cells for 30 
minutes in 1% albumin in PBS. The cells were incubated in primary FITC goat anti-rabbit 
antibody for 10 hours, washed, then incubated with secondary AlexaFluor 546 (Life 
Technologies, Grand Island, NY)) for 1 hour in the dark. The nuclei were stained with Hoechst 
33342 DNA-dye at 1/10,000 for 1 min (Life Technologies, Grand Island, NY). After a final wash 
within the chamber slides, cells were imaged using an inverted digital, wide-view, and confocal 
microscope. Preparation for publication was completed using Photoshop® (Adobe) software as 
described previously (Dibble, Bencharit et al, 2010). 
In silico Analysis  
In silico analysis was completed using software from Phyre ™ software11, followed by 
PyMol ™ software for imaging (The PyMOL Molecular Graphics System, Version 1.7.4 
Schrödinger, LLC.). This form of prediction analysis uses the known structure of a given protein 
based on  protein X-ray crystallography.11 The protein sequence containing the altered 
sequence of interest was interrogated by the software that uses previously scanned protein 
structures, their corresponding validated protein sequences, and the knowledge of molecular 
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interactions to fabricate a best-fit-model. The resulting prediction was provided in the form of a 
3D image of a protein.11 
Results 
Phenotypic presentation of 1092delG and 966_997insC PTH1R mutations 
The 1092delG mutation, which resulted in a frameshift and truncated PTH1R protein, was 
selected for the functional studies described here for many reasons (Figure 2.10). From a 
clinical standpoint, this novel mutation was associated with the clinical finding of infraoccluded 
primary teeth, and was identified in a small nuclear family (N=2).  The non-syndromic index 
case was a 7 years, 9 months old male who exhibited PFE affection of the permanent and 
primary teeth in the form of a right lateral posterior open bite, mild Class lll skeletal 
malocclusion, and an early-onset dilaceration of a PFE-affected 1st permanent molar (Figures 
2.11a and 2.11b (Rhoads et al, 2013).29 Another mutation, the previously identified 
966_997insC PTH1R mutation, was also selected to model the subsequent protein structure 
(Figure 2.12 (Rhoads et al, 2013). Similar to the 1092delG, another mutation, 996_997insC, was 
selected because of affection of the primary dentition with early-stage dilacerations of the PFE-
affected 1st permanent molar. 12 This frameshift mutation segregated in a family as Type I PFE in 
affected individuals. Of those affected, two presented with one-jaw only patterning, and two 
with a bilateral maxillary and mandibular pattern.  Unaffected individuals in this family (n=5) did 
not carry the 996_997insC mutation and did not reveal any signs of the dental eruption 
phenotype, indicating an autosomal dominant inheritance with complete penetrance.12 
Notably, systemic and/or skeletal problems were detected in this family. Five individuals 
indicated a previous diagnosis of early onset arthritis by a medical doctor manifesting in the 
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back and/or hip region around the second or third decade of life (Table 2.1).12 The functional 
alterations identified in our study were not refined enough to decipher how the development 
of osteoarthritis progression is related to the mutational pathology.   
Variation in WT vs 1092delG PTH1R protein localization using IFA 
There were observed differences between the expression of the WT and Mutant PTH1R as 
visualized by IFA. Although these differences were not specifically quantified, it was noted that 
the WT PTH1R (Figures 2.8a, b, and c) bound and concentrated itself at the membrane in higher 
levels than that of the mutant (Figure 2.9). This suggests that the mutant’s ability to fully bind 
to the cell membrane is diminished due to the mutation. The intensity of the WT stain was 
more pronounced, and the transport vesicles appeared more vibrant and concentrated, in 
comparison to the mutant.  
Genotype: Protein Sequence (1092delG and 996_997insC PTH1R mutations) 
The 1092delG PTH1R mutation results in an a altered amino acid sequence extending 
from  the transmembrane-5 (TM5) loop through transmembrane-7 (TM7), before shifting back 
into frame near the beginning of the c-terminus. The number of amino acids of the 1092delG 
protein is approximately 81 amino acids (AAs) short of the WT, although the c-terminus is 
conserved. The 996_997insC mutation resulted in a frameshift mutation that affected the 
regions of the transmembrane-4 (TM4) and TM5 loops. The protein was truncated; however its 
c-terminus was conserved. Most importantly, both of the aforementioned mutations alter the 
amino acids that constitute the 3rd intracellular loop, which are central to G-protein interaction. 
These important amino acids are Val 384, Leu385, Thr387, and Lys388.3 Taken together, these 
findings support and validate these identified mutations and their respective protein alteration 
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sites for use in more specific, g-protein activation pathway interrogation. Figures 2.13, 2.14, and 
2.15 illustrate the genotype: protein domain correlations, current database of PTH1R DNA: 
protein mutations, and a graphical depiction of the mutated regions of the PTH1R protein.  
In silico Predictions of WT PTH1R, 1092delG, and other functional PTH1R mutations 
We submitted WT and mutated protein sequences identified in our lab (1092delG, 1353-
1 G>A, 966_997insC, 572delA) into Phyre2 ™ and visualized the resultant proteins via PyMol ™ 
(Figures 2.16a-e). All mutated predictions resulted in an altered, truncated protein with a slight 
alteration of the transmembrane c-terminus.  However, within our current database of 
functional PTH1R mutations, the 1092delG mutation is the only one that caused a downstream 
alteration within the 6th TM loop. Additionally, while the c-terminus is conserved based on the 
amino acid sequence, the c-terminus of the 1092delG protein is truncated and altered to the 
greatest extent (Figure 2.15b). This is in comparison to the 996_997insC PTH1R mutation that 
led to a downstream alteration in the 3rd intracellular loop, and had a moderately altered c-
terminus in comparison to the collection of current PTH1R mutations. All of the predictions 
yielded a reported confidence of 100%.   
Discussion 
Reduction of Mutant PTH1R Cell Surface Presence  
 While the potential alteration in G-protein coupling is a compelling argument, the 
functional study demonstrated that the mutated protein is less localized in the cell membrane 
as compared to the WT. This reduction in cell membrane localization supports the postulation 
that part of the consequence of the 1092delG mutation is the reduction of cell membrane 
localization, resulting in a decline of the appropriate signal transduction response to 
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PTH/PTHrP. Future studies that interrogate downstream effectors can further confirm whether 
there is an actual defect in the signal transduction pathway. An important place to begin such 
queries would be the enzymes critical for the G-protein signaling cascades (ie, AC, PLC, PKC, and 
PKA). 
In silico Analysis 
Computer modeling is a useful tool in the intellectual journey of improving our 
understanding of the molecular and structural consequence of PTH1R mutations, however, it 
has its limitations. In silico analysis, by its very nature, is a prediction of structure.  It is a 
structural interpretation based on a limited database, albeit a very educated one. The reliability 
of an in silico analysis is centered on the reliability of its database, however, the absolute 
validity of our prediction results are strengthened by our functional studies. Indeed, the gestalt 
of our in silico analysis reveals differences in the protein structure that appear consistent with 
the location of the mutation but more importantly these studies can be used to support further 
and more pointed inquiries into the results of a PTH1R mutation.  
PTH1R Mutation Potentially Affects G-Protein Binding 
The in silico protein prediction of the WT v. the 1092delG, 1353-1 G>A, 966_997insC, 
572delA predictions, resulted in truncated protein mutants with an altered intracellular c-
terminus. However, the most remarkable of the protein predictions is the structural alteration 
of the 1092delG and 996_997insC PTH1R mutations. Although the c-terminus was conserved in 
both cases, each mutation led to downstream alterations that spanned key locations within the 
TM or intracellular loops; with each region being highly relevant for normal g-protein binding 
and signaling.3 We can therefore postulate that the alterations in the c-terminus, 3rd 
23 
intracellular loop, and the TM6 loop creates an altered G-protein binding pattern. Furthermore, 
the fact that both of the identified mutations affected the very 4 amino acids critical for 
efficient G-protein coupling increases the probability of functional disruption. This is 
substantiated, in part, by our understanding that PTH1R can bind to different G-proteins, some 
of which, have antagonistic effects within the somatic and cell system.28 It is plausible that the 
TM, intracellular loop, and c-terminus alterations caused the PTH1R protein to bind to a G-
protein that 1) has greater antagonistic activity towards the eruption process; 2) did not allow 
the receptor to bind to a protein at all, or 3) lead to an altered up or downstream regulatory 
pathway. 
Primary PFE Tooth Affection, 1092delG and 996_997insC 
The observation that both mutations represent unique cases in our database with PFE 
affection of primary teeth and the early stages of permanent 1st molar dilaceration is 
significant. These mutations are associated with the infraocclusion of primary teeth, and based 
on knowledge of the sequence they are the only mutations that affect key G-protein binding 
sites within locations of PTH1R. Therefore, isolating G-protein uncoupling occurring within 
these mutations could help identify the signaling pathway responsible for an integral part of 
eruption. Moreover, the affection of primary teeth potentially represents a more extreme 
manifestation of PTH1R malfunction; isolating the pathway of primary tooth eruption failure 
will aid in elucidating the pathway to permanent tooth eruption and eruption failure.   
G-Protein Conformational Change Alterations and Ligand Binding 
Since two mutations clearly affected TM3 and TM6 loops as discussed above, we 
considered their respective roles.  It is known that TM3 and TM6 loops are critical in terms of 
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their altered G-protein affinity and basal signaling.3 Alterations in PTH1R conformation can also 
result in varying affinities for different ligands. Furthermore, PTH1R exists in two different G-
protein related conformations: 1) RG, in which the receptor is bound to it G-protein, and 2) Ro, 
in which the receptor is not coupled to a G-protein.28 PTH and PTHrP have been shown to bind 
similarly to the G-protein coupled PTH1R conformations, however PTH has a much greater 
binding affinity, than PTHrP in relation to the uncoupled G-protein PTH1R conformation. This 
confers that when PTH1R is in its Ro conformation, PTH has much greater signal production 
capability than PTHrP.33 Depending on the GPCR conformation, PTH and PTHrP will have 
different initial binding affinities to the receptor, as well as varying stability during its existence 
as the ligand-receptor complex. This concept is important to ponder when evaluating the 
potential effects of the 1092delG mutation and can help explain the different modes of ligand 
activity (endocrine v. paracrine). For instance, if the conformation of the receptor, due to the 
frameshift mutation, creates an inability able to bind effectively to the G-protein or the 
required ligand- a breakdown in the classical pattern of PTH1R function may be imminent.28 
Dimeric Oligomerization Activation/Deactivation of the Homodimeric PTH1R Complex 
In the 1092delG mutation we can consider the findings of Xu et al. In their study, it was 
determined that the crystal structure of the ligand-free PTH1R extracellular domain (ECD) forms 
an α-helix, which mimicks PTH/PTHrP by effectively occupying the peptide binding groove of its 
opposing protomer.27 PTH binding was shown to disrupt receptor oligomerization via functional 
studies, as predicted by their model and a receptor reduced to a monomeric state by mutations 
in the ECD retained wild-type PTH binding and cAMP signaling ability. PTH1R therefore forms a 
constitutive dimer that is dissociated by the binding of a ligand. The Xu lab also showed that a 
25 
monomeric PTH1R is able to couple with, and activate, a G-protein.27 These findings are highly 
relevant to the results of our functional studies which showed that the diminished activity of 
one mutant PTH1R copy is likely tied to a decrease in G-protein activation. This also aligns with 
the varying degrees and types of PFE presentation because we suspect that if the overall 
activation of the coupled G-protein is attenuated, it is possible that the threshold for normal 
eruptive function is not met- which can result in the apparent temporal and spatial variations of 
eruption failure. 
Future Studies 
The functional studies described in this paper suggest that the mechanism of the clinical 
affection is likely partially due to the aberrant expression or localization of the PTH1R protein, 
but also represents a situation where a potentially large percentage of the mutation’s affect is 
loss of function; such as altered ligand binding or alterations in G-protein coupling.  Based on 
these results we predict that this functional defect in the protein may act to disrupt the 
membrane binding, intracellular signaling, and G-protein binding; however, future studies are 
needed to interrogate downstream targets. 
 The use of bioluminescence (BRET) and fluorescence resonance energy transfer (FRET) 
techniques that would enable us to investigate the receptor oligomerization and interaction in 
living cells is one way to extend our interrogation. Reducing the amount of DNA used to 
transfect the COS7 cells in order to produce increased contrast of protein expression will 
provide a clearer image of localization. Additionally, the use of more specific confocal imaging, 
RT-PCR, specific binding assays, and quantitative Western blots are additional potential 
methods to further extrapolate data surrounding the function of PTH1R, and PTH1R in PFE. 
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Conclusions 
1. The 1092delG PTH1R mutation results in the reduction of the protein’s ability to localize and 
bind to the cell membrane. 
2.  Identified amino acid alterations in the PTH1R transmembrane region, specifically the 3rd 
intracellular loop, affects the functional aspect of protein function. 
3. Two (2) functional mutations affected TM6 and the third intracellular loops are specifically 
related to the eruption failure of primary teeth. 
4. Further studies are needed to determine the functional effect of a PTH1R mutation, such as a 
RT-PCR, fractionation, a quantitative western blot, functional binding assays, bioluminescence 
(BRET),  fluorescence resonance energy transfer (FRET) techniques, and  transfection at a lower 
DNA concentration level. 
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CHAPTER TWO 
 
MUTATIONAL ANALYSIS OF TNFSF-11 AND BMP2 IN PFE AFFECTED PATIENTS 
 
Introduction 
The presentation of eruption disorders among the human population presents the 
dental practitioner with a plethora of differential diagnoses, connected to a diverse set of 
phenotypes. Primary Failure of Eruption (PFE) (OMIM ID: 125350) was first described by Proffit 
and Vig, and is defined as a failure of the eruption mechanism itself7, which cannot be 
explained by a syndrome or a mechanical interference.8 A hallmark of PFE is that these teeth do 
not respond favorably to orthodontic traction and, in fact, attempted orthodontic treatment 
often results in a worsened malocclusion and increased open bite due to intrusion of adjacent 
teeth.1, 2, 9  PFE clinically presents as the infra-occlusion of affected teeth, resulting in a 
posterior open bite malocclusion (Figure 3.1 (Frazier Bowers et al, 2009)). Typically, all teeth 
distal to the most mesially affected tooth also fail to erupt.9 The diagnosis of PFE is critical as it 
dictates that treatment with continuous archwires should be avoided. Some successful 
treatment has been reported by multiple individual tooth osteotomies or selective individual 
tooth extractions followed by implant restorations to restore a functional occlusion.8  The 
connection between PFE and PTH1R has been documented in multiple labs across the world.
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PTH1R and PFE 
Our current understanding of eruption disorders has been strengthened by human 
genetic studies which have highlighted mutations in parathyroid hormone receptor 1 (PTH1R) 
as a causative factor for familial cases of PFE.1, 2, 8, 9 A study of nine family members revealed 
PTH1R as an autosomal dominant mutation associated with a PFE phenotype. All family 
members with PFE had a mutation in the PTH1R gene in this study, while those without PFE 
lacked this mutation.8 PTH1R mutations associated with PFE have in silico predictions that 
result in the formation of truncated proteins with a somewhat conserved c-terminus. 
Haploinsufficiency has been suggested to be part of the underlying cause of PFE, in which 
insufficient amounts of functional receptors are formed from the unaffected allele. Non-
syndromic PFE patients do not exhibit any peripheral signs of the disease, and it may be 
hypothesized that this mutation causes a disruption confined to alveolar bone in the epithelial-
to-mesenchymal (EMT) crosstalk signaling pathways that are necessary for normal bone 
resorption and apposition in tooth eruption.8, 9 Taken together, this implicates genetic 
mutations in PTH1R as diagnostic and causative of PFE and is important in the context that 
many patients diagnosed with PFE and confirmed by the presence of a mutation in PTH1R were 
initially misdiagnosed with ankylosis.1, 2  Both PFE and ankylosis preferentially affect molars and 
posterior teeth making them even more difficult to distinguish from one another.2  
PFE: A Diagnostic Challenge 
The contrast between ankylosis and PFE are just examples of the complexity and 
overlapping nature of eruption disorders. Treatment decisions, and therefore the success of the 
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treatment, rely heavily on accurate diagnosis and treatment planning. The fact that we have a 
method to genetically and clinically diagnose individual disorders is a promising new frontier in 
medicine, due to the fact that the connection between the etiology and the clinical 
presentation of patients are not always as obvious. This can be seen specifically, in one family, 
in which five members carried the same mutation in PTH1R, but two affected individuals 
carrying this mutation were diagnosed incorrectly with ankylosis through percussion testing 
(see Figure 3.2).8 This scenario further reveals a gap in the knowledge and points to the 
difficulty in clinically distinguishing PFE from other eruption disorders (i.e. ankylosis or 
mechanical failure of eruption - MFE).  PFE is a poorly understood problem of tooth eruption 
that with more investigation will improve our understanding of the biology of normal tooth 
eruption, but also the diagnosis of eruption failure.  
Mutational Analysis Studies of PTH1R 
The foundation for the mutational studies described herein was based on the database 
of functional and non-functional PTH1R mutations previously identified and described in the 
Frazier-Bowers’ Lab.12 Studies in this laboratory revealed that while six of twelve families with 
PFE segregate mutations in PTH1R, the remaining cohort lack functional mutations in PTH1R, 
further suggesting other gene(s) as causative of PFE.12,18,29  These findings also revealed a novel 
inheritance pattern in PFE, incomplete penetrance and therefore forms the basis for an 
additional research question, whether modifier genes contribute to PFE. 12   
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Phenotypic Analysis of PFE 
 PFE has been analyzed from a genetic and clinical perspective.  Clinical analysis of 
photos and radiographs evaluated the following: jaw-affection, bilateral or unilateral affection, 
super- or infraosseous tooth position, and the clinical Type of PFE. Broadly, PFE is divided into 
two subtypes, Type 1 and Type 2. Type 1 PFE presents as a progressive, anterior-posterior 
lateral openbite that worsens distal to the most mesially positioned PFE-affected tooth; Type 2 
PFE presents with a more varied pattern of infra-eruption distal to the most mesially affected 
tooth.17 The affected members in each family group had varied clinical PFE presentations. This 
variation was noted as both between and within familial segregating mutations. Of those 
families with functional mutations, four families were classified as Type I PFE, while the other 
two families were classified as either Type II or having a mixture of Type I and Type II 
presentations.  All of the affected individuals who provided records were found to have an 
eruption failure that manifested during the supraosseous phase (i.e. the teeth had emerged 
partially through the bone), and unilateral versus bilateral eruption failure (i.e. manifesting on 
one side of the dental arches) occurred equally. 
The Interaction of BMP2, TNFSF-11, and PTHrP in Tooth Eruption 
 PTHrP has been shown to be integral to tooth eruption through the observation of 
increased concentration of PTHrP levels in the dental follicle and stellate reticulum at the 
initiation of eruption.5 The coronal region of the dental follicle regulates osteoclastogenesis and 
the apical region is responsible for bone formation. CFS-1, localized in the superior region of the 
dental follicle, up-regulates osteoclast precursor cells and down-regulates osteoprotegerin 
(OGP), which is a soluble decoy receptor for RANK. Additionally, PTHrP, which is produced by 
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the stellate reticulum cells in a paracrine manner, up-regulates TNFSF-11 expression in dental 
follicle cells.5 This same hormone results in the production of vascular endothelial growth factor 
(VEGF), which up-regulates the producing of RANK receptors on osteoclast precursors.5 Taken 
together, this results in more available RANK receptors interacting with increased levels of 
TNFSF-11, leading to osteoclastogenesis and eruption pathway clearance. The apical region of 
the dental follicle has a relatively higher concentration of BMP2, which is responsible for 
alveolar bone formation via osteoblasts. PTHrP causes the apical dental follicle cells to up-
regulate BMP2 production.5 Taken together, it was determined that BMP2 and TNFSF-11 were 
plausible candidate genes to investigate in terms for their potential role in PFE and eruption.      
Ingenuity Pathway Analysis (IPA) 
Ingenuity Pathway Analysis (IPA) was performed (Figure 3.3) to inform our understanding 
of high-priority candidate genes for PFE based on interactions with PTH1R.  IPA revealed that 
multiple genes involved in craniofacial development interact with PTH1R (e.g. PTHRP, TNFSF-11, 
TGFB1, BMP2, BMP6).   As a result of this analysis and based on the literature, we chose to 
interrogate the role of BMP2 (20p12.3) and TNFSF-11 (13q14.11) (hRANKL) in the development 
of PFE. Our rationale to study these particular candidate genes was strengthened by the 
intimate connection between the periodontal ligament (PDL), TNFSF-11, PTH1R, and 
PTHrP/PTH.28 
Materials and Methods 
Ascertainment of Families and Diagnosis 
Approval for this study was granted by the Biomedical Institutional Review Board (IRB) 
at the University of North Carolina at Chapel Hill.  Every adult participant, or parental guardian 
32 
in the case of minors, provided their consent to participate in this study.  Typically, the index 
case was identified through a referring orthodontist.   Fifteen cases were selected for analysis 
of BMP2 and TNFSF-11 based on the negative results of these probands following sequencing of 
the PTH1R gene.  Probands lacking functional mutations in the PTH1R gene, despite clinical 
signs of PFE, ranged in age from 6 – 68 years.  Previously collected phenotypic data was 
analyzed for characterization of non-functional genetic alterations. All probands (N=15) had 
pre-treatment clinical photographs, panoramic and cephalometric radiographs following the 
initial clinical assessment, as described below. 
A positive PFE phenotype diagnosis was made based on at least one infraoccluded first 
molar using clinical data (ie radiographs, and/or examination at minimum).  A clinical interview 
was completed for each affected individual and/or their family members to determine general 
health status and the elimination of any syndromic patients. Index cases (individuals of interest) 
were identified based on their affection with PFE, as determined from radiographic and clinical 
presentation, as well as their lack of a functional PTH1R mutation. DNA was extracted using 
Oragene Salivary Kit and using the manufacturer’s protocol. 
Phenotypic Analysis  
Clinical (phenotypic) information was collected and reviewed for the individuals 
harboring a nonfunctional PTH1R, TNFSF-11, or BMP2 mutation. The records assessed included 
a minimum of a panoramic radiograph and intraoral clinical photographs. The following 
information was gathered:  
1) Unilateral or bilateral presentation of infraoccluded teeth 
2) Arch involved (affected teeth present in the maxilla, mandible, or both) 
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3) Presence or absence of any other abnormal or noteworthy findings, including the 
significant involvement of primary teeth 
Additionally, the type of PFE, Type I or II (determined by the degree of eruption of the second 
molars) was recorded. 
The classification of PFE was recorded as either Type I or II, as previously described in 
the literature.2, 17 These types are distinguished based on the timing of onset.  Briefly, Type 1 
PFE is characterized by a progressive posterior open bite, in which all teeth distal to the most 
mesial infra-occluded tooth are affected and do not erupt into occlusion. Type 2 PFE exhibits 
greater eruption potential, although still inadequate, for the more distal teeth, such as second 
molars.   
A phenotypic analysis was completed for each individual that was clinically diagnosed 
with PFE in our cohort of inquiry. With the use of clinical photographs and radiographs, PFE 
affection was described as either unilateral or bilateral, and PFE pattern was described as either 
Type 1 or Type 2. All of the current PFE cases within this cohort are of European decent.  
Mutational Analysis of BMP2 and TNFSF-11 
Mutational analysis was performed following extraction and purification of DNA from 
saliva (Oragene, DNA Genotek, Toronto, Canada) for all individuals in this study. We amplified 
and sequenced all coding exons of BMP2 (3 exons- only 2 coding exons) and TNFSF-11 (4 
exons), included identifying common synonymous SNPs and non-synonymous (deleterious) 
mutations. Sequencing was performed on 15 probands using designed primer sets. To include 
splice junctions in our analysis, primer sets were designed to delineate regions that included a 
minimum of 25 bases of intron sequence in addition to the exon sequence. Amplification was 
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performed using HotStart polymerase chain reaction (PCR) buffer and enzyme mix (Life 
Technologies/Invitrogen, Bethesda, MD) under the following conditions: 10 min 95°C 
activation/premelt, followed by 35 cycles of 30 s at 94°C melt, 30 s at 60°C anneal, and 3 min of 
72°C extension. PCR products were purified using ExoSaplt (USB, Cleveland OH), and sequenced 
at the University of North Carolina at Chapel Hill Genome Analysis Core facility. Sequences were 
compared to wild type TNFSF-11 and BMP2 (accession NM_003701 and accession 
NC_000020.10) from Genbank release GRCh37 using the BLAST algorithm.   
Ingenuity Pathway Analysis (IPA) 
Based on Ingenuity Pathway Analyses (Ingenuity Systems, Inc.) several candidate genes 
have documented interactions with one another. The interactions that are presented in 
connection with an IPA are varied and vast. Therefore, it was determined to focus primarily on 
TNFSF-11 and BMP2 due to the strong association with PTH1R in the pathway analysis, as well 
as their involvement with the eruption process.  
Results 
Mutational Analysis 
               Analysis of both BMP2 and TNFSF-11 candidate genes in PFE-affected patients who did 
not carry a mutation in PTH1R (N=15) resulted in the identification of 3 intronic SNPs in TNFSF-
11, without any compelling genetic alterations in BMP2, to-date. Two SNPs were located within 
Exon 5 and one was located within Exon 8.  
The intronic SNPs in TNFSF-11 have been previously documented in NCBI: c.387+14G>A 
(21% minor allele frequency), c.533-34T>A (3.4% minor allele frequency), and c.220-75T>G 
(.042% minor allele frequency) (1000Genomes). The global minor allele frequency (MAF) 
35 
(reported by NCBI - dbSNP) is the minor allele frequency for each SNP ID in a default global 
population. Global MAF distinguishes common polymorphism from rare variants. The MAF is 
actually the second most frequently occurring allele value. The current default global 
population is generated from the 1000 Genomes phase 1 genotype data, which has a 
collection of 1094 worldwide individuals (released in the May 2011) (NCBI).  The relatively rare 
allele of at least 2 SNPs identified in association with PFE, c.533-34T>A (3.4% minor allele 
frequency), and c.220-75T>G (.042% MAF) suggest the possibility of a functional role of these 
SNPS that do not represent common variants. 
Phenotypic Analysis 
     After a comprehensive analysis of index cases, (Table 3.1) it was determined that 75% of 
reported TNFSF-11 SNP-containing genotypes of sequenced individuals presented with a 
bilateral, 2-jaw, supraosseous affection; of which both the premolars and molars were affected. 
A total of 75% of PFE affected individuals presented with a Type I pattern, and the remaining 
with a Type II pattern.  However, only 50% of the bilaterally affected side had a Type I 
presentation. Out of our cohort of PFE affected, non-functional alterations; the majority (78%) 
presented with a bilateral affection, and 56% of individuals presented with Type 1 PFE (Chart 
3.1). It was also noted, that no particular trend in affection appears to sequester with any SNP in 
particular (Chart 3.2 and 3.3). 
Discussion 
       BMP2 and TNSFS-11 were prioritized for this project because BMP2 is highly active in the 
basal region of the dental follicle and is responsible for root formation and apical bone 
apposition; while TNFSF-11 has been found to be highly active in the superior region of the 
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dental follicle and is critical for bone resorption.5  Hence, choosing these two genes was 
supported by network pathway analysis, the current understanding of eruption pathways, and 
eruption studies in a rat model.5,28 The identification of 3 SNPs in TNFSF-11 represents 
continued progress in developing an understanding of PTH1R, PFE, and the eruption process. It 
is well understood, from the literature, pathway analyses and our geneotype:phenotypes 
studies, that PTH1R is not likely the sole gene responsible for eruption disorder, specifically PFE.  
Our interrogation of TNFSF-11 and BMP2 was based on their involvement in calcified tissue 
metabolism, tooth eruption, and PTH1R interactions.  
Currently, TNFSF-11 is the most promising in terms of our current findings. Although 
only putatively non-functional SNPs have been identified, it cannot be definitively determined 
how they affect the other genes in an up or downstream manner.19 Studies have shown that 
intronic mutations can cause alterations in genes both near and far from the intronic location. 
There are four different classes of pre-mRNA splicing defects that have been found to cause 
disease: cis-acting mutations that disrupt the use of constitutive splice-sites (most common 
cause of human diseases), cis-acting mutations that disrupt alternative splice-sites, trans-acting 
mutations that affect the basal splicing machinery, and lastly; trans-acting mutations that 
cause the disruption of splicing regulation (cause for cancers, myotonic dystrophy, etc).19 
            This concept has also been validated in terms of Calpain-10 (diabetes) and BRCA1/2 
(breast cancer). Intronic mutations can lead to splice-site alterations- which in turn, can lead to 
many different outcomes.19 Due to the fact that genes undergo alternative splicing patterns 
during replication; this allows different copies of slightly alternative proteins to be created from 
the same pre-mRNA. Keeping in mind that different cells and cell systems have varying 
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sensitivities to particular mutations, conditions, and varying protein product produced- of 
which range from redundant to problematic. The fact that one SNP identified, c.220-75T>G, 
resents a MAF of only .042% (ie low frequency in the population) strengthens the potential of 
further evaluation. In order to determine the effect of the intronic SNPs identified in TNFSF-11, 
we would need to pursue more eloquent studies, such as performing a miRNA assay, in order to 
determine the effect of the mutated intron- before it is removed from the protein sequence. 
Future Study- Whole Exome Sequencing (WES) 
Whole Exome Sequencing (exomic) is an efficient and powerful tool to identify novel 
genes that may contribute to PFE.  WES was developed in recent years to accomplish extensive 
sequencing primarily targeted to rare genomic variation that leads to protein-coding changes.  
In this case, WES would be implemented to assess a single family in our database that harbors 
PFE clinical affection, but lacks a functional PTH1R mutation.  Complete phenotypic 
characterization (based on a rigorous clinical rubric: Rhoads et al., 2013) has been completed 
for all of the individuals in the family, along with analysis of PTH1R.  Collaboration has already 
been established with Dr. J. Evans (NCGENES Project) and his team, and the inclusion of our 
families/samples was approved.  The following stipulations/assumptions have been made: in 
order to participate only one affected individual per family for WES (up to 5 five families) were 
provided; these individuals were deemed to have a genetic condition that does not show a 
mutation in genes known to be associated with their condition (i.e. PTH1R has already been 
excluded); participants in the NCGENES must consent to participate and attend two visits at the 
NCGENES central hub (Jim Evans clinical site). 
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Conclusions 
1. Currently 3 intronic SNPs have been identified in TNFSF-11, which supports the inclusion of 
other genes to PFE and eruption, besides PTH1R. 
2. c.220-75T>G, resents a MAF of only .042%, and further strengthens the need to continue  
interrogating theses SNPs due to the low frequency of occurrence in the global population. 
3. There have been no BMP2 alterations identified in PFE cohort, to-date. 
4. Continued studies of candidate genes with WES and PCR (TNFSF-11 and BMP2) are needed to 
conclude other genetic causes of PFE. 
miRNA assay of current SNPs is needed to determine the functionality of present TNFSF-11 
mutations. 
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Tables 
Table 2.1- Correlation of Genotype: phenotype of 4 families with segregating PFE.  Family 1 
shows four affected individuals carrying the mutation. One individual has PFE affected primary 
teeth.  Family 2 shows incomplete penetrance with 2 individuals carrying mutation but not 
affected with the eruption phenotype. Two individuals were not available for testing and both 
reported eruption failure (*). One is able to note the familial segregation of each PTH1R 
mutation observed. Family 4 demonstrates two PFE affected members carrying a mutation, 
with one having PFE affected primary teeth 
 
Table 1: Genotype 
:Phenotype Functional 
PTH1R Mutations 
    
  PFE  Affection Publication  Mutation 
        
Family 1             
I:1                      
II:2 
II:3 
II:4 
Type I 
Type I 
Type I 
Type I-Primary 
 Frazier-Bowers et al. 2013 
“ 
“ 
“ 
 c.996_997insC 
c.996_997insC  
c.996_997insC 
c.996_997insC 
Family 2            
I:1                      
II:2 
II:4 
III:1 
III:2 
unaffected 
unaffected 
Affected* 
Type I 
Affected* 
 Frazier-Bowers et al. 2013 
“ 
“ 
“ 
“ 
 c.572delA 
c.572delA 
c.572delA 
N/A 
N/A 
Family 3             
III:2                     
II:2 
III:3 
III:4 
Type II 
Type I 
Type I 
Type II 
 Frazier-Bowers et al. 2010a 
“ 
“ 
“ 
 c.1353-1 G>A 
c.1353-1 G>A 
c.1353-1 G>A 
c.1353-1 G>A 
Family 4             
II:1                      
I:2 
Type II-Primary 
Affected* 
 
 Rhoads et al. 2013 
“ 
 1092delG 
1092delG 
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Table 3.1- Mutational Analysis Results of PFE affected individuals lacking functional PTH1R 
mutation. The results are shown in combination with SNP data from PTH1R ( non-functional  
mutations) and phenotypic presentation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Family 1 PFE  Status Affection Pattern
PTH1R Genetic Alteration/ 
SNP
TNFSF-11 Genetic 
Alteration/ SNP
1 Unaffected N/A no alteration
2 Unaffected N/A no alteration
3 Unaffected N/A no alteration
4 Affected - Type I Bilateral/ Supraosseous c. 1389 T>C, known variant
Family 2
1 Unaffected N/A no alteration
2 Affected  undetermined  c.638+97G>A, intronic
3 Affected - Type II Unilateral/ Supraosseous  c.638+97G>A, intronic
Family 3
1 Unaffected N/A no alteration
2 Unaffected N/A no alteration
3 Affected - Type I Bilateral/ Supraosseous c. 646 C>A, synonymous
4 Unaffected N/A c. 646 C>A, synonymous
5 Unaffected N/A no alteration
Family 4
1 Affected - Type II Bilateral/ Supraosseuos c. 1389 T>C, known variant
2 Affected - Type II Bilateral Supraosseous c. 1389 T>C, known variant
3 Affected – Type UNK UNK c. 1389 T>C, known variant
Family 5
1 Affected- Type I Unilateral/Supraosseous no alteration rs227439
Family 6
1 Affected- Type II Bilateral/Supraosseous no alteration rs76238184
Family 7
1 Affected- Type I Bilateral/Supraosseous no alteration rs227439
Family 8
1 Affected- Type I Bilateral/Supraosseous no alteration rs12721447
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Figures 
Figure 1- Clinical photograph of child in the mixed dention, presenting with a posterior lateral 
open bite- secondary to a lateral tongue thrust. The tongue acts as a mechanical impedence to 
tooth eruption.   
 
 
Figure 2- Patient with a functional familial PTH1R mutation, originally diagnosed as having 
ankylosis. As a result of mutational analysis of PTH1R it was determined that PFE was in fact the 
correct diagnosis and that if orthodontic treatment was pursued, PFE affected teeth should be 
avoided. 
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Figure 3- Frontal intraoral photos of (A) before and (B) after-orthodontic treatment in a patient 
with a subsequently confirmed case of PFE. This patient had a positive family history of PFE, and 
harbored a familial autosomal dominant mutation in the PTH1R gene. After treatment with a 
continuous archwire, the PFE affected teeth ankylosed and resulted in a worsened posterior 
openbite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 4- Jansen’s Metaphyseal Chondrodysplasia is caused by autosomal dominant                
heterozygous mutations in PTHR1 resulting in short limbed dwarfism. (Taken from 
http://www.gfmer.ch/genetic_diseases_v2/gendis_detail_list.php?cat3=200) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5- Bloomstrand’s Lethal Chondrodysplasia exhibits a recessive PTHR1 mutative 
deactivation which results in early lethality, shortened limbs, and premature bone maturity. 
(Taken from http://jcem.endojournals.org/content/vol92/issue3/images) 
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Figure 6- The Human PTH1R gene is located on the short (p) arm of chromosome 3 between 
positions 22 and 21.1. The region is bracketed in red.  (http://ghr.nlm.nih.gov/gene/PTH1R) 
 
 
 
 
Figure 2.1- Bloomstrand’s Lethal Chondrodysplasia exhibits a recessive PTHR1 mutative 
deactivation. This deactivation results in early lethality, shortened limbs, and very precocious 
bone maturity. The fetus does not usually carry to term. 
(http://www.eurorad.org/eurorad/case.php?id=1463) 
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Figure 2.2- PFE results from a autosomal dominant PTH1R mutation. The classical presentation 
is a progressive anterior-posterior lateral openbite shown in 2.2a and 2.2b. PFE is unique to the 
PTH1R mutations in that it only affects the dental units. (Frazier-Bowers et al. 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2a 
2.2b 
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Figure 2.3- Diagram of the pcDNA3.1 + vector used contain the WT PTH1R insert. It contains an 
ampicillin and neomycin vector to ensure selectability after transformation and transfection. 
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Figure 2.4- Vector constructed by the Gardella laboratory. The pcDNA 3.1 (+) vector was 
implemented to carry the WT PTH1R insert. The resultant vector was named TG682 7260.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5a- Nucleotide sequence segment of interest. The area highlighted in green denotes 
the section of interest for the site-directed mutagenesis of WT PTH1R.   
  acttgagctc cgggaacaaa aagtggatca tccaGGtgcc catcctggcc tccattgtgc 
       
Figure 2.5b- Nucleotide sequence segment of interest. The highlighted area of the sequence 
denotes the region of the 1092delG PTH1R mutation where a G was deleted. This sequence was 
used as the blueprint for the site-directed mutagenesis of the TG682 7260 WT PTH1R vector. 
  acttgagctc cgggaacaaa aagtggatca tccaGtgcc catcctggcc tccattgtgc 
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Figure 2.6- 48 hour post transfection of COS7 cells with pcDNA 3.0 (+GFP insert). This 
transfection was used as an approximation of transfection efficiency- which was determined to 
be 70%. 
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Figure 2.7- Confocal Image of 24 hours post-transfection of WT PTH1R/COS7 cell. This image 
illustrates the movement of the protein (fluorescence) from the nucleus, into the endoplasmic 
reticulum, and then into transport vesicles. Definitive cell membrane concentration had not yet 
been reached. 
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Figure 2.8a- Immunoflourence assay (IFA) was utilized during visualization (Inverted digital 
microscope) of the PTH1R protein in terms of localization and expression. 48 hours post 
transfection with WT PTH1R v blank control, IFA demonstrated normal expression of PTH1R 
protein and an intact nucleus (visualized via DAPI). 
  
 
Figure 2.8 b and c- 48 Hours Post-Transfection of WT PTH1R/COS7 cell (Inverted digital 
microscope). IFA was implemented to visualize protein expression, normal expression was 
founds, as well as a more intense illumination of transport vesicles and noted areas of PTH1R 
protein membrane intensity, in comparison with the mutant, imaged below. Figures b and c are 
both WT PTH1R, however, antibodies of different fluorescing wavelengths were used for initial 
imaging. 
 
 
 
B C 
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Figure 2.9- 48 Hours Post-Transfection of 1092delG PTH1R/COS7 Cell (Inverted digital 
microscope). IFA was implemented to visualize mutated PTH1R protein expression. Heavy peri-
nuclear intensity can be noted , as well as relatively normal expression 
 
 
Figure 2.10- Chromatogram demonstrating the familial 1092delG in the PTH1R gene, linked to 
infraocclusion of primary teeth in an affected child. 
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Figure 2.11a- Panoramic radiograph demonstrating the involvement of both primary and 
permanent teeth in the affected patient who carries a 1092delG mutation in PTH1R. Note that 
the affected right mandibular 1st molar has the appearance of early-stage dilaceration in the 
region of the apical 3rd- similar to the patient bearing the 996_997insC PTH1R mutation, a 
dilaceration of an affected left permanent mandibular 1st molar is observed. (Rhoads et al, 
2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11b- Intraoral clinical photographs 12 of PFE presentation in a 7yo 9 mo patient whose 
1092delG mutation was the foundation for the COS7 Cell functional study. This is the second 
case of PFE found to have a genetic linkage to a PTH1R mutation and affection of the primary 
dentition. Credit Dr. AB Hammond (Rhoads et al, 2013) 
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Figure 2.12- Chromatogram demonstrating the familial 996_997insC mutation in the PTH1R 
gene. This mutation is one of two mutations linked to infraocclusion of primary teeth in an 
affected child. (Rhoads et al, 2013)  
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Figure 2.13- Exon:Domain Pairing of hPTH1R. Note that the functional exons are depicted, along 
with the denotation of the corresponding protein domains.  
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Figure 2.14- WT, 572G>A, 996_997insC, 1353delA, and 1092delG PTH1R Protein sequences with 
Transmembrane, extracellular, and intracellular loops labeled. Note the downstream 
involvement of the 3rd intracellular loop and the TM6 loop domain with 996_997insC and 
1092delG PTH1R mutations, respectively. 
 
PTH1R Proteins in PFE Families 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50         60                 
HPTHR1 WT    MGTARIAPGL ALLLCCPVLS SAYALVDADD VMTKEEQIFL LHRAQAQCEK RLKEVLQRPA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      70         80         90        100        110        120              
HPTHR1 WT    SIMESDKGWT SASTSGKPRK DKASGKLYPE SEEDKEAPTG SRYRGRPCLP EWDHILCWPL  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     130        140        150        160        170        180           
HPTHR1 WT    GAPGEVVAVP CPDYIYDFNH KGHAYRRCDR NGSWELVPGH NRTWANYSEC VKFLTNETRE  
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     190        200        210        220        230        240           
HPTHR1 WT    REVFDRLGMI YTVGYSVSLA SLTVAVLILA YFRRLHCTRN YIHMHLFLSF MLRAVSIFVK  
  572DelA    REVFDRLGMI SPWATPCPWR PSP* 
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     250        260        270        280        290        300           
HPTHR1 WT    DAVLYSGATL DEAERLTEEE LRAIAQAPPP PATAAAGYAG CRVAVTFFLY FLATNYYWIL  
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350        360           
HPTHR1 WT    VEGLYLHSLI FMAFFSEKKY LWGFTVFGWG LPAVFVAVWV SVRATLANTG CWDLSSGNKK  
  996_997Ins VEGLYLHSLI FMAFFSEKKY LWGFTVFGWG LPRCLRGCVG QCQSYPGQHR VLGLELREQK 
 
 
  
                                     
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     370        380        390        400        410        420           
HPTHR1 WT    WIIQVPILAS IVLNFILFIN IVRVLATKLR ETNAGRCDTR QQYRKLLKST LVLMPLFGVH  
  (996’)     VDHPGAHPGL HCAQLHPLHQ YRPGARHQAA GDQRRPV* 
  1092delG   WIIQCPSWPP LCSTSSSSSI SSGCSPPSCG RPTPAGVTHG SSTGSCSNPR WCSCPSLAST 
 
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     430        440        450        460        470        480           
HPTHR1 WT    YIVFMATPYT EVSGTLWQVQ MHYEMLFNSF QGFFVAIIYC FCNGEVQAEI KKSWSRWTLA  
  1353-1G>A                                    Deleted in PFE-01 (Exon 15 skip) 
  1092delG   TLSSWPHHTP RSQGRSGKSR CTMRCSSTPS RDFLSQSYTV * 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     490        500        510        520        530        540           
 
TM1 TM2 
TM4 
TM7 
TM6 TM5 
TM3 
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HPTHR1 WT    LDFKRKARSG SSSYSYGPMV SHTSVTNVGP RVGLGLPLSP RLLPTATTNG HPQLPGHAKP 
        
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     550        560        570        580        590        600           
 
HPTHR1 WT    GTPALETLET TPPAMAAPKD DGFLNGSCSG LDEEASGPER PPALLQEEWE TVM*PGAGGW  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|.. 
                     610        620        630        640               
HPTHR1 WT    TC*HSGWTDG PKDGWLNDFP LRAGAKRKNR EKKKKKRKRK RKKKKKK 
 
Extracellular Loop 
Intracellular Loop 
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Figure 2.15-This chart denotes the transmembrane loops and the locations of the functional 
mutations in PTH1R, identified in the Frazier-Bowers Laboratory. It is important to note that 
996_997insC and 1092delG mutations affect the TM4-TM7 regions, including the 3rd 
intracellular loop. TM6 and the 3rd intracellular loop have been determined to be instrumental 
in G-protein affinity and binding.  
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Figure 2.16a- In silico prediction of WT PTH1R. Note the intact animo/carboxyl- tails, as well as 
the 7-transmembrane loops. 
 
  
 
 
 
 
Figure 2.16b- In silico prediction of 572delA PTH1R mutation. This mutation resulted in an 
alteration in the region of TM1. 
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Figure 2.16c- In silico prediction of 996_997insC PTH1R mutation. This mutation lead to 
downstream alterations, including those within the 3rd intracellular loop. 
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 Figure 2.16d- In silico prediction of 1092delG PTH1R mutation. This mutation lead to 
downstream alterations, including the region of TM6 and 3rd intracellular loops. 
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Figure 2.16e- In silico prediction of 1353-1G>A PTH1R mutation. This alteration affected a small 
region of the c-terminus. 
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Figure 3.1- Initial radiograph of patient presenting with clinic sings of Primary Failure of 
Eruption (PFE) in the region of the  lower left permanent molar. Affection of at least one 
permenenet molar is a hallmark sign of PFE.  
 
 
 
Figure 3.2- Patient with a functional familial PTH1R mutation, initially diagnosed as having 
ankylosis. As a result of genetic testing- it was determined that PFE was the correct diagnosis 
and that if orthodontic treatment was pursued, PFE affected teeth should be avoided. (Frazier-
Bowers et al, 2010) 
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Figure 3.3- Ingenuity Pathway Analysis (IPA) of the interaction of multiple genes with PTH1R. 
The genes of interest were TNFSF-11 and BMP2. The interaction of other notable genes, such as 
BMP4, RUNX2, and BMP6 are potential future candidate genes, and are possible hits expected 
through the Whole Exome Sequencing (WES) which is currently underway. 
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Figure 3.4- Chromatograms exhibit three TNFSF-11 SNPs c.387+14G>A (21% MAF), c.533-34T>A 
(3.4% MAF), and c.220-75T>G (.042% MAF). These SNPS are intronic, yet could still lead to 
downstream functional mutations. (1000 genomes©) 
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Charts 
 
Chart 3.1- This chart displays the overall patterning of phenotypic expression in the cohort of 
comparable PFE patients with evident non-functional alterations in either PTH1R or TNFSF-11. 
The majority (78%) show bilateral affection and Type 1 patterning (56%). 
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Chart 3.2- This illustrates the distribution of individuals carrying non-functional alterations that 
are affected with either Type 1 or 2 PFE, within each mutation identified. A majority of the 
cohort demonstrated Type 1 affection. 
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Chart 3.3- Table demonstrating the distribution of Unilateral versus Bilateral Affection in PFE 
patients that had a non-functional alteration. It is easily seen that the vast majority presented 
with bilateral affection. It can be taken from both sets of cohort data, that bilateral, Type 1 
affection is most prevalent in the present cohort of PFE patients with non-functional mutations. 
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